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Summary
Background—Erlotinib is approved for the treatment of all patients with advanced non-small 
cell lung cancer (NSCLC), but is most active in the treatment of EGFR mutant NSCLC. 
Cabozantinib, a small molecule tyrosine kinase inhibitor, targets MET, VEGFR, RET, ROS1, and 
AXL, which are implicated in lung cancer tumorigenesis. We tested the efficacy of cabozantinib 
and the combination of erlotinib plus cabozantinib, as compared with erlotinib, in patients with 
EGFR wild-type NSCLC.
Methods—In this three arm, randomised phase 2 study, the primary endpoint was to compare 
progression-free survival (PFS) of patients treated with cabozantinib versus erlotinib alone, and 
the combination of erlotinib plus cabozantinib versus erlotinib alone. Patients were eligible if they 
had received 1–2 previous treatments for advanced non-squamous EGFR wild-type NSCLC. 
Patients were stratified by performance status and line of therapy, then randomised using permuted 
blocks within strata to receive open label oral daily dosing of erlotinib (150 mg), cabozantinib (60 
mg), or erlotinib (150 mg) and cabozantinib (40 mg). Imaging was performed every 8 weeks. At 
the time of radiographic progression, there was optional crossover for patients in either single 
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agent arm to receive combination therapy. The comparison between erlotinib and each of the arms 
was powered (91%) to detect a PFS hazard ratio (HR) of 0.5 (1-sided p-value 0.10-level). 
Secondary objectives were overall survival (OS), radiographic response by RECIST version 1.1 
and description of adverse events by CTCAE version 4.0. This trial is registered with 
ClinicalTrials.gov, number NCT01708954.
Findings—At complete enrollment, we randomised 125 patients (42 assigned to erlotinib, 40 
assigned to cabozantinib, 43 assigned to the combination), of which 111 (89%) were eligible and 
received treatment per protocol were included in the primary analysis (38, 38, and 35 patients on 
erlotinib, cabozantinib, and combination, respectively). Compared to erlotinib alone (median 1.8 
months), PFS was significantly improved in the cabozantinib arm (4.3 months, HR 0.39, 1-sided 
p=0.0003, 80% CI 0.27–0.55) and also in the erlotinib plus cabozantinib arm (4.7 months, HR 
0.37, 1-sided p=0.0003, 80% CI 0.25–0.53).
The safety analysis population included all patients who received study therapy regardless of 
eligibility. The most common grade 3 or 4 adverse events were diarrhea (3 [8%] in the erlotinib 
group vs 3 [8%] in the cabozantinib group vs 11 [28%] in the erlotinib and cabozantinib group), 
hypertension (none vs 10 [25%] vs 1 [3%]), fatigue (5 [13%] vs 6 [15%] vs 6 [15%]), oral 
mucositis (none vs 4 [10%] vs 1 [3%]), and thromboembolic event (none vs 3 [8%] vs 2 [5%]). 
Adverse events that were grade 3 or worse occurred in 13 (33%) patients in the erlotinib group, in 
28 (70%) patients in the cabozantinib group, and in 28 (72%) patients in the erlotinib and 
cabozantinib group. One death of respiratory failure occurred in the cabozantinib group, deemed 
possibly related to either drug or disease, and one death occurred in the erlotinib plus cabozantinib 
group from pneumonitis. MET IHC results were available on 86 patients from the primary analysis 
and 85% were scored as positive (1–3+ membrane or cytoplasm staining with MET4 antibody). 
There was no association between MET IHC status and PFS when treated with or without 
cabozantinib.
Interpretation—The ECOG-ACRIN 1512 trial design tested the feasibility of using cabozantinib 
alone or combined with erlotinib in this patient population with EGFR wild-type NSCLC. Despite 
its modest sample size, this trial identified signals of clinically meaningful efficacy superior to that 
of erlotinib alone, and additional toxicity that was generally manageable. Cabozantinib-based 
regimens are promising for further investigation in this patient population.
Keywords
Non-small cell lung cancer; Erlotinib; Cabozantinib; Epidermal growth factor receptor
Introduction
Lung cancer remains the leading cause of cancer-related deaths worldwide, killing more 
than 1.3 million people annually.(1) In non-squamous non-small cell lung cancer (NSCLC), 
first-line chemotherapy with a platinum-based doublet for advanced disease has a historical 
response rate of only approximately 20–30% and a median overall survival of 8–10 months.
(2) At the time of progression, second-line chemotherapeutic agents such as docetaxel and 
pemetrexed confer benefit with response rates of approximately 10% and progression-free 
survival times of approximately 3 months.(3, 4) Over the last year, immunotherapeutic 
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checkpoint inhibitor antibodies such as nivolumab and pembrolizumab also have been 
demonstrated to improve outcomes in the second line treatment of NSCLC as compared 
with docetaxel.(5, 6)
NSCLC adenocarcinomas can be categorized into groups by driver genomic alterations, and 
an overall survival benefit has been observed in patients that received appropriate targeted 
therapy based on genomic profiling of their tumors.(7) The most common driver is a 
mutation in the EGFR gene, present in approximately 15% of NSCLC adenocarcinomas. 
Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is 
highly active in the treatment of tumours harboring EGFR mutations.(8) However, more than 
75% of NSCLC adenocarcinomas have neither an EGFR mutation (described as EGFR wild-
type) nor another targetable genomic alteration. In these patients, erlotinib therapy is 
sometimes used based on a decade-old trial, which demonstrated a 2 month survival benefit 
for erlotinib as compared with placebo in second and third line treatment of NSCLC.(9) This 
historical use of erlotinib in wild-type EGFR NSCLC formed the basis for the selection of 
the erlotinib control arm in this study of EGFR wild-type NSCLC.
Cabozantinib is an orally available TKI that is active against MET and vascular endothelial 
growth factor receptor-2 (VEGFR2), and also RET, ROS1, AXL, KIT, and TIE-2. MET 
dysregulation in non-small cell lung cancers by protein overexpression, mutations, and gene 
amplification can be therapeutically targeted in patients using MET inhibitors (10–12). 
VEGFR2 is a primary mediator of VEGF-stimulated angiogenesis, and anti-angiogenic 
strategies have been effective in the treatment of NSCLC. Preclinical studies have 
demonstrated that MET amplification can be a mechanism of acquired resistance to EGFR 
inhibitors, and that targeting both MET and EGFR synergistically inhibits proliferation of 
many cancer cell lines.(13, 14) Cabozantinib was selected for this study in EGFR wild-type 
NSCLC because MET protein is expressed in approximately 50% of these tumors, and anti-
angiogenic therapy appears effective even in wild-type disease. (12, 15, 16) A single arm 
phase II study of cabozantinib had previously demonstrated that cabozantinib was active as a 
single agent in the treatment of NSCLC, with a response rate of 10%, disease control rate of 
40% and progression-free survival of 4.2 months.(17) Another phase I/II trial showed that 
the combination of erlotinib and cabozantinib could safely be administered together.(18)
When this study was conceptualized, testing of tumors for EGFR mutations to predict 
sensitivity to erlotinib was the standard of care in the United States, but patients with 
advanced EGFR wild-type NSCLC refractory to chemotherapy often still received erlotinib 
in the second and third line setting. We conducted this trial to directly compare the efficacy 
of erlotinib with cabozantinib, and to compare erlotinib with cabozantinib plus erlotinib, in 
patients with previously treated EGFR wild-type advanced NSCLC. The primary objective 
was to determine whether single agent cabozantinib or combination therapy including 
cabozantinib extends progression-free survival (PFS) when compared to single agent 
erlotinib for this patient population. Secondary objectives were estimation of overall 
survival, best objective response, and toxicity. A retrospective analysis was planned to 
determine the association of MET expression by immunohistochemistry with outcomes.
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Methods
Study design and participants
We conducted this multicenter, randomised phase II trial within the ECOG-ACRIN Cancer 
Research Group; accrual by institution is listed in appendix (page 9). Complete eligibility 
criteria are listed in the appendix (page 1). Briefly, patients were included who had 
metastatic or recurrent non-squamous NSCLC which had progressed following first line 
platinum-doublet chemotherapy, and optionally progressed following a second-line 
chemotherapy regimen. Patients were not allowed to have prior erlotinib or MET TKI 
therapy. Testing for EGFR TKI sensitizing mutations - at minimum, exon 19 deletions and 
L858R point mutations - was performed by local sites prior to screening for the trial, and 
patients with these or other known EGFR TKI sensitizing mutations were excluded. 
Submission of paraffin embedded tissue was required for retrospective MET testing by 
immunohistochemistry. Patients were required be >= 18 years old and have measurable 
disease by RECIST 1.1 criteria, and patients were allowed to have previously treated and 
stable brain metastases. Other eligibility criteria included ECOG performance status of 0–2, 
adequate bone marrow, renal, hepatic, and cardiac function, and no hemoptysis, tumor 
invasion of large vessels or organs, or recent surgery, chest irradiation, or major thrombotic 
events. The institutional review boards at each participating institution approved the study 
protocol and amendments. All patients in the trial provided written informed consent. The 
study complied with the Declaration of Helsinki and was done in accordance with Good 
Clinical Practice guidelines.
Randomisation and masking
The three treatment arms were open-label erlotinib monotherapy, cabozantinib monotherapy, 
and the combination of erlotinib and cabozantinib. Randomisation (1:1:1) to these arms was 
determined using permuted blocks within strata with dynamic balancing institutions. 
Randomisation was stratified by number of prior therapies (1 vs. 2) and ECOG performance 
status (0 vs. 1 vs. 2). Neither patients nor investigators were blinded to assigned treatment.
Procedures
Following assignment to treatment, the first dose of study drug was administered within 5 
working days. Erlotinib was prescribed as standard-of-care therapy by the treating physician 
to patients on the erlotinib arms at a dose of 150 mg orally daily. Cabozantinib-s-malate was 
distributed from CTEP via the local research pharmacy and administered at a dose of 60 mg 
orally daily in the monotherapy arm, and 40 mg orally daily in the combination arm. 
Toxicity was graded according to the National Cancer Institute common toxicity 
terminology criteria for adverse events (NCI-CTCAE) version 4.0. Dose reduction levels for 
intolerable grade 2, grade 3, and grade 4 drug-related events were as follows: erlotinib: 100 
mg, 50 mg; cabozantinib 40 mg, 20 mg. A maximum of 2 dose reductions or 28 day drug 
hold to recover from toxicity was allowed, or patients were removed from the study. 
Management guidelines were provided in the protocol for diarrhea, rash, and other 
anticipated toxicities; some toxicities allowed continuation of dose after hold, some required 
dose reduction, and some required permanent discontinuation.
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A cycle of therapy was defined as 4 weeks. Monitoring tests for safety (complete blood 
count, comprehensive metabolic panel, magnesium, phosphorus, thyroid function testing, 
electrocardiogram) was performed every 2–4 weeks. Radiographic tumour assessment was 
performed at baseline and every 2 cycles (8 weeks) according to RECIST 1.1 criteria by site 
investigators without central image review.(19) There was no limit to length of therapy as 
long as patients had radiographically controlled disease and managed toxicity. At the time of 
radiographic progression, patients in the erlotinib or cabozantinib single agent therapy 
groups were allowed to crossover to combination treatment with erlotinib plus cabozantinib 
or discontinue treatment.
MET testing was performed in the Center for Molecular Oncologic Pathology at the Dana 
Farber Cancer Institute/Brigham and Women’s Hospital. The laboratory was blinded as to 
study arm. Total MET IHC testing was performed on the Leica Bond III automated 
immunostainer using the Bond Refine Detection system on 4-μm sections of FFPE(formalin 
fixed, paraffin embedded) specimens with the rabbit polyclonal c-Met clone CVD13 
(ThermoFisher Scientific, Waltham, MA, USA) and both membranous and cytoplasmic 
staining were scored from 0–3+ intensity, and percentage positivity, respectively.
Outcomes
The primary endpoint was progression-free survival (PFS), defined as the time from 
randomization to documented disease progression or death from any cause, whichever 
occurs first. Patients who had not experienced an event of interest by the time of analysis 
were censored at the date they are last known to be alive and progression-free. Overall 
survival was defined as the time from randomization to death from any cause, and patients 
who were thought to be alive at the time of final analysis were censored at the last date of 
contact. Best objective response was evaluated via RECIST1.1 criteria. Toxicity was 
determined using CTCAE v4.0 criteria. The MET outcome analysis was a pre-planned 
exploratory endpoint.
Statistical analysis
The primary comparison was designed to accrue and randomise 105 eligible and treated 
patients 1:1:1, for a total accrual of 35 patients to each of the 3 arms. After adjusting for an 
ineligibility rate of 10%, the total estimated sample size for randomisation was 117 patients. 
Using an overall one-sided 0.10 level log rank test for each comparison, this study had 91% 
power to detect a PFS hazard ratio of 0.50, which corresponds to an improvement in the 
median PFS from 2.4 months on the control arm to 4.8 months on either experimental arm. 
The number of PFS events needed to achieve this power for each comparison was 58 events 
under the alternative hypothesis. Each of the two primary comparisons of PFS used a log 
rank test stratified on the randomisation stratification factors with a one-sided type I error 
rate of 10%. PFS was defined as the time from randomisation to documented disease 
progression or death from any cause, whichever occurred first. Patients who had not 
experienced an event of interest by the time of analysis were censored at the date of the last 
radiographic disease assessment.
Neal et al. Page 6
Lancet Oncol. Author manuscript; available in PMC 2017 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The primary endpoint was assessed in the per protocol population, which was defined as all 
patients who were eligible, randomly assigned, and received at least one dose of treatment. 
Patients were radiographically assessable if there was RECIST 1.1 measurable disease and 
all sites were evaluated within 4 weeks of starting therapy and a minimum of 8 weeks after 
starting therapy. The safety analysis population included all patients who received study 
therapy regardless of eligibility. MET IHC outcome analysis included the primary analysis 
population with tissue and MET result available. Overall survival was defined as the time 
from randomisation to death from any cause, and patients who were known to be alive at the 
time of final analysis were censored at the last date of contact. PFS and OS distributions 
were estimated using the Kaplan-Meier method, and Cox proportional hazards models were 
used to estimate the treatment hazard ratios. Response rates and toxicity were compared 
using Fisher’s exact tests. This study was monitored by the ECOG-ACRIN Data Safety 
Monitoring Committee (DSMC) with one planned interim analysis for futility of PFS at 
roughly 50% information using the methodology of Freidlin, Korn, and Gray; at that time, if 
either point estimate of the PFS HR was consistent with detriment (HR > 1.0), the DSMC 
may have considered terminating the respective comparison early for overall lack of 
treatment difference.(20) The study was followed to full information, and at that time the 
DSMC recommended that the results be released and that patients still receiving erlotinib 
only be offered one of the other treatments. The software used to conduct the analyses was R 
version 2.10.0. This trial is registered with ClinicalTrials.gov, number NCT01708954.
Role of the funding sources
The sponsor of this trial was ECOG-ACRIN, a United States grant-funded multidisciplinary, 
membership-based scientific organization which was formed by the merger of the Eastern 
Cooperative Oncology Group (ECOG) and the American College of Radiology Imaging 
Network (ACRIN). ECOG-ACRIN was responsible for approving study design, 
development, coordinating enrollment, data collection, data management, audits, a pre-
planned interim futility analysis, and the final data analysis. ECOG-ACRIN participated in 
the interpretation of data together with the other co-authors, and reviewed the report. SD had 
full access to the data, and JWN reviewed and certified the data. Bio-specimens were 
collected, processed and made available for correlative studies by the ECOG-ACRIN 
Pathology Coordinating Office and Reference Laboratory. Exelixis supplied cabozantinib for 
this trial through a cooperative research and development agreement (CRADA) with the 
National Cancer Institute Cancer Therapy Evaluation Program. The corresponding author 
had the final responsibility to submit for publication.
Results
Between February 7, 2013 and July 1, 2014, we completed enrollment of 125 patients and 
randomly assigned them to erlotinib (n=42), cabozantinib (n=40), or erlotinib plus 
cabozantinib (n=43). Fourteen (11%) of 125 patients never started assigned therapy or were 
deemed ineligible, leaving 111 (89%) patients in the primary analysis (Figure 1). At the time 
of data cutoff for this analysis, August 31, 2015, 33 (30%) patients in the primary analysis 
population were alive. The median follow-up was 17.0 months (15.4 months for erlotinib, 
23.4 months for cabozantinib, and 14.9 months for erlotinib plus cabozantinib, with 
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interquartile range for all groups of 12.7 – 23.1 months). Patient demographics and disease 
characteristics were generally balanced (table 1) with the exception of ethnicity, history of 
brain metastases, mediastinal metastases (p=0.03), and prior immunotherapy.
Exposure to therapy was assessed for each group. The median number of cycles received by 
treatment group were: 2 cycles for erlotinib (range: 1–10); 3 cycles for cabozantinib (range: 
1–17); and 2 cycles for erlotinib plus cabozantinib (range: 1–15). Planned or unplanned dose 
modifications were experienced by 29 (76%) of 38 eligible and treated patients in the 
erlotinib group; 36 (95%) of 38 in the cabozantinib group; and 34 (97%) of 35 in the 
erlotinib plus cabozantinib group. The data collected did not capture the reason for dose 
modification, although the protocol only permitted dose modification due to adverse events, 
not at investigator’s discretion, The average daily dose of erlotinib was 140.2 mg of erlotinib 
for the erlotinib group and 125.5 mg of erlotinib for the erlotinib plus cabozantinib group. 
The average daily dose of cabozantinib was 52.6 mg for the cabozantinib group and 31.7 mg 
for the erlotinib plus cabozantinib group.
Table 2 summarizes the efficacy results. Progression-free survival was statistically 
significantly better in the cabozantinib group than in the erlotinib group (HR=0.39, 80% CI 
[0.27–0.55], 1-sided p=0.0003); it was also better in the cabozantinib plus erlotinib group 
than in the erlotinib group (HR=0.37, 80% CI [0.25–0.53], 1-sided p=0.0003). Multivariable 
Cox models were fitted to adjust for imbalanced baseline variables and prognostic factors, 
and results were consistent with the unadjusted model. The estimated median PFS and 
corresponding 95% CI on each treatment arm was 1.8 months (1.7–2.2 months) on erlotinib, 
4.3 months (3.6–7.4 months) on cabozantinib, and 4.7 months (2.4–7.4 months) on erlotinib 
plus cabozantinib. Figure 2A displays PFS by treatment arm. Overall survival was also better 
in the cabozantinib group than in the erlotinib group (HR=0.68, 80% CI [0.49–0.95], 1-sided 
p=0.07); it was statistically significantly better in the cabozantinib plus erlotinib group than 
in the erlotinib group (HR=0.51, 80% CI [0.35–0.74], 1-sided p=0.01). The estimated 
median OS and corresponding 95% CI on each treatment arm was 5.1 months (3.3–9.3 
months) on erlotinib, 9.2 months (5.1–15.0 months) on cabozantinib and 13.3 months (7.6-
NA months) on erlotinib plus cabozantinib. Figure 2B displays overall survival by treatment 
arm. Response rate was measured using RECIST 1.1 criteria, and objective responses did 
not differ significantly between the groups (Table 2). There was one partial response (PR) in 
the erlotinib group with a 48% reduction in tumor, four PRs in the cabozantinib group with 
median reduction of 36% (range 30–53%), and one PR in the erlotinib plus cabozantinib 
group with a 33% reduction in tumor. A total of 19 (17%) of 111 patients from the 
monotherapy arms crossed over to start combination therapy: 13 (34%) of 38 crossed over 
from erlotinib, and 6 (16%) of 38 crossed over from cabozantinib. No radiographic 
responses (complete response or PR) were observed in patients who crossed over to 
combination chemotherapy.
Tissue samples were collected on all patients at baseline for central MET IHC testing. 
Membranous and cytoplasmic staining were individually scored, and positivity was declared 
if MET was expressed in either the membrane or cytoplasm. A total of 107 independent 
patient samples were tested. Twelve samples were excluded from the analysis due to no 
sufficient tumor tissue available for scoring. From the 95 remaining samples, 86 came from 
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the primary analysis population of eligible and treated patients. The overall of MET 
positivity in tissue samples was 73 (85%) of 86; by group it was 24 (80%) of 30 on erlotinib, 
26 (81%) of 32 on cabozantinib, and 23 (96%) of 24 on erlotinib plus cabozantinib. Per 
protocol, we combined the cabozantinib treated groups for this analysis. MET status was not 
a significant predictor of PFS in a model also adjusted for whether or not a patient received 
cabozantinib: the estimated PFS HR for MET positivity was 0.65 (2-sided p=0.19). 
Progression-free survival by MET status is displayed in figure 3. The median PFS among 
MET-negative patients randomised to erlotinib was 1.9 months (95% CI: 1.7 months - NR); 
for MET-negative patients who received any cabozantinib it was 4.4 months (95% CI: 1.8 
months - NR). The median PFS among MET-positive patients randomised to erlotinib was 
1.8 months (95% CI: 1.6–2.9 months); for MET-positive patients who received any 
cabozantinib it was 5.0 months (95% CI: 3.9–7.4 months). Testing of additional MET 
positive cutpoints (cytoplasmic, membranous, or either) did not demonstrate that these were 
a significant predictor of PFS either (data not shown).
Adverse events
Selected adverse events of interest are presented in Table 3, and all treatment-related adverse 
events are presented in the appendix (page 3). The most common grade 3 or 4 adverse events 
were diarrhea (3 [8%] in the erlotinib group vs 3 [8%] in the cabozantinib group vs 11 
[28%] in the erlotinib and cabozantinib group), hypertension (none vs 10 [25%] vs 1 [3%]), 
fatigue (5 [13%] vs 6 [15%] vs 6 [15%]), oral mucositis (none vs 4 [10%] vs 1 [3%]), and 
thromboembolic event (none vs 3 [8%] vs 2 [5%]). Hypertension was significantly higher in 
the cabozantinib group compared with the erlotinib group (2-sided p=0.001), as was diarrhea 
in the erlotinib plus cabozantinib group compared with the erlotinib group (2-sided p=0.02). 
Adverse events of grade 3 or worse occurred in 13 (33%) patients in the erlotinib group, and 
were significantly higher in the cabozantinib group (28 patients [70%], 2-sided p=0.001), 
and in the erlotinib and cabozantinib group (28 patients [72%], 2-sided p=0.002). In the 
erlotinib group, 3 patients discontinued treatment for adverse events, compared with 11 
patients in the cabozantinib group, and 13 patients in the erlotinib and cabozantinib group. 
Deaths on or within 30 days of last dose of treatment included 7 (17%) in the erlotinib 
group, 3 (8%) in the cabozantinib group, and 7 (16%) in the cabozantinib plus erlotinib 
group, and are presented in the appendix (page 8). All were deemed unlikely or unrelated to 
treatment, except for two: one death due to respiratory failure in the cabozantinib group, 
deemed possibly related to either drug or disease, and one death in the erlotinib plus 
cabozantinib group from drug pneumonitis due to either agent or the combination.
Discussion
Our findings show that cabozantinib treatment alone, or cabozantinib plus erlotinib, was 
associated with a statistically significant improvement in progression-free survival when 
compared to erlotinib alone in patients with EGFR wild-type NSCLC who progressed after 
prior therapy. This treatment effect was supported by a corresponding improvement in 
overall survival, albeit with an increase in toxicity.
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The results for the control arm were consistent with other trials using erlotinib in EGFR 
wild-type patients. During the conduct of this study, other trials were reported that used 
erlotinib as a control arm in EGFR wild-type NSCLC, in comparison to second line single 
agent chemotherapy. In the Italian TAILOR trial, 222 patients were randomised to erlotinib 
or docetaxel.(21) Median overall survival was 8.2 months with docetaxel, compared with 5.4 
months with erlotinib (adjusted hazard ratio (HR) 0.73, 95% CI 0.53–1.00; p=0.05), and 
median progression-free survival (PFS) was 2.9 months with docetaxel versus 2.4 months 
with erlotinib (adjusted HR 0.71, 95% CI 0.53–0.95; p=0.02). In the Japanese DELTA trial, 
301 patients were randomly assigned to erlotinib or docetaxel. (22) In a subset analysis of 
199 patients with EGFR wild-type tumors, OS for erlotinib versus docetaxel was 9.0 v 10.1 
months (HR, 0.98; 95% CI, 0.69 to 1.39; P = 0.91), and PFS for erlotinib versus docetaxel 
was 1.3 versus 2.9 months (HR, 1.45; 95% CI, 1.09 to 1.94; P = 0.01). The phase 3 TITAN 
study randomised 424 patients to erlotinib versus docetaxel or pemetrexed chemotherapy.
(23) No differences in OS or PFS were identified between the groups, even for the EGFR 
wild-type subgroup, although EGFR mutation status was indeterminate or missing on more 
than half of patients. Overall, these studies consistently observe modest efficacy of erlotinib 
in EGFR wild-type NSCLC, and suggest inhibiting other non-EGFR signaling pathways is a 
rational treatment strategy in this subgroup of patients. Our observed median PFS of 1.8 
months was similar to the 1.3, 1.4, and 2.4 months observed on the DELTA, TITAN, and 
TAILOR trials, respectively. Our observed median OS of 5.1 months was similar to the 5.3 
and 5.4 months observed on the TITAN and TAILOR trials, but less than the 9.0 months 
observed in the DELTA trial. In addition, the PFS on the cabozantinib monotherapy arm of 
4.3 months was quite similar to the 4.2 months previously observed in the previously 
conducted single arm phase II study of cabozantinib, and OS on this study was not reported. 
Therefore, the favorable efficacy outcomes observed in both experimental arms in our study 
are both clinically and statistically significant.
Cabozantinib therapy, or the combination of cabozantinib and erlotinib, was associated with 
an increased occurrence of grade 3 or worse adverse events compared with erlotinib alone. 
Many of these adverse events were symptomatic, such as fatigue, nausea, oral mucositis, and 
palmar-plantar erythrodysesthesia syndrome, all more frequently associated with 
cabozantinib treatment. The previous phase I/II trial of erlotinib and cabozantinib 
demonstrated that cabozantinib needed to be reduced to 40 mg daily in combination with 
erlotinib to limit diarrhea; despite this, patients still received an average of 32 mg of 
cabozantinib daily on the combination arm. While not statistically imbalanced for this 
randomised trial, the fatal adverse events of respiratory failure and pneumonitis, and life 
threatening adverse events of intracranial hemorrhage, thromboembolic event, other skin 
disorder, and thrombocytopenia were only observed on the cabozantinib arms. This suggests 
that cabozantinib is potentially less tolerable than erlotinib, though given its more potent 
clinical benefit this may be a worthwhile tradeoff. The recent FDA approval of cabozantinib 
60 mg daily for renal cell carcinoma suggests that it has an acceptable overall safety profile 
as monotherapy.
Given the potential mechanism of action as a MET inhibitor, it was hypothesized that MET 
protein expression might be predictive of response to cabozantinib. However, no effect was 
observed on PFS by MET status in the subset of patients in whom MET IHC testing and 
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response assessment was available. Additionally, cabozantinib is known to inhibit AXL, 
which may be activated together with other driver tyrosine kinases. While there is no 
standardized assay for AXL expression, a biomarker may be identified in an ongoing clinical 
trial of cabozantinib that includes patients with NSCLC that has increased AXL activity 
(NCT01639508). Cabozantinib also may be exerting its clinical benefit as a VEGFR2 
inhibitor. It is known that VEGFR2 inhibition is effective in the second line treatment of 
NSCLC, as a VEGFR2 monoclonal antibody, ramucirumab, is FDA approved in 
combination with docetaxel based on a median overall survival of 10.5 months compared 
with 9.1 months for docetaxel alone (HR 0.86, 95% CI [0.75–0.98]; p=0.023).(15) 
Additionally, the small molecule VEGFR2 inhibitor nintedanib plus docetaxel is active in 
patients with adenocarcinoma histology, with a median overall survival of 12.6 months 
versus 10.3 months for docetaxel alone (HR 0.83 [95% CI 0.70–0.99], p=0.0359), which led 
to approval by European regulatory agencies (24). However, no broadly validated predictive 
biomarker of anti-angiogenic therapy has been identified to date.
Limitations of this study include the modest sample size and the lack of detailed molecular 
driver oncogene characterization. Although effects on overall survival were observed, a 
larger trial would be needed to confirm these results. However, conducting a larger trial of 
similar design would be challenging. We believe that erlotinib is no longer a suitable control 
arm for a confirmatory trial given the mounting evidence that erlotinib is minimally effective 
in an EGFR wild-type NSCLC population. One potential comparator would be docetaxel, 
with a median PFS of 3.0 months and median OS of 9.1 months in a recent large randomised 
trial.(15) Another potential comparison therapy would be nivolumab, which was superior to 
docetaxel in non-squamous NSCLC for median OS (12.2 months for nivolumab vs 9.4 
months for docetaxel) but not median PFS (2.3 months for nivolumab vs 4.2 months for 
docetaxel). However, with numerical medians of PFS and OS similar to those we observed 
for cabozantinib, it appears unlikely that cabozantinib monotherapy would be superior to 
either docetaxel or nivolumab in a randomised trial. Another limitation is that we only 
collected known KRAS driver oncogene status, and limited tissue exists to pursue further 
testing which has become a standard of care in the intervening years since the study began. 
It is possible that potential cabozantinib sensitive molecular drivers such as RET 
rearrangement, ROS1 rearrangement, and MET amplification or MET exon 14 skipping 
mutation were imbalanced between the groups, leading to the observed survival benefits of 
cabozantinib. This is unlikely, because we would predict all of these to total no more than 
10% of this study population, and patients with these alterations would be expected to have 
radiographic responses to targeted therapy. Few such responses were observed on this trial, 
even in the cabozantinib groups, suggesting that individual patients with particularly 
sensitive disease were unlikely to be imbalanced across the arms. Therefore, it is unlikely 
that a small subgroup with particular molecular driver alterations was responsible the 
observed clinical benefit of cabozantinib, though testing of remaining tissue is of interest.
To our knowledge, ECOG-ACRIN 1512 is the first randomised study to show that 
cabozantinib, either alone or in combination with erlotinib, improved progression-free 
survival and overall survival compared with single agent erlotinib in EGFR wild-type 
NSCLC in the 2nd and 3rd line setting. Despite the increased toxicity profile, this suggests 
that cabozantinib is worthy of further study in this patient population. ECOG-ACRIN 
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investigators plan to initiate a follow-up study to build on these observations and further 
delineate a role for cabozantinib in the treatment of advanced non-squamous NSCLC.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Research in Context
Evidence before this study
In developing the study design and protocol, we did a systematic review of the scientific 
literature. We searched PubMed, with no time restrictions; abstracts of major oncology 
meetings; and trial websites including ClinicalTrials.gov, for preclinical data and clinical 
trials assessing chemotherapy in patients with lung cancer, EGFR therapies in these 
patients, MET inhibitor therapies in these patients, and the combination of these methods. 
Search terms included “non-small cell lung cancer”, “EGFR”, and “MET”.
Clinical data in support of this trial included a phase 2 study cabozantinib in patients with 
previously treated NSCLC which showed that it was active in generating objective 
tumour responses and meaningful time to progression of disease. Additionally a phase 
1/2 trial of erlotinib and cabozantinib demonstrated the safety of the combination of these 
drugs. Based on our review of the literature and discussions with clinicians, researchers, 
and regulatory bodies, we postulated that combining erlotinib with cabozantinib might 
improve treatment efficacy in patients with previously treated EGFR wild-type advanced 
non-squamous non-small cell lung cancer.
Added value of this study
Our study shows significant improvement in progression-free survival in patients who 
were treated with cabozantinib, or the combination of cabozantinib and erlotinib, as 
compared with erlotinib alone. There was also a signal of improvement in overall survival 
observed in these groups. We found no evidence of associate of progression-free survival 
with MET status as determined by immunohistochemical staining.
Implications of all the available evidence
The ECOG-ACRIN 1512 trial design tested the feasibility of using cabozantinib alone or 
combined with erlotinib in this patient population with EGFR wild-type NSCLC. Despite 
its modest sample size, this trial identified signals of clinically meaningful efficacy 
superior to that of erlotinib alone, and additional toxicity that was generally manageable. 
Further investigation of cabozantinib in this patient population, potentially in 
combination with other established therapies, is warranted.
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Figure 1. 
Trial profile
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Figure 2. 
Kaplan-Meier estimates of progression-free survival and overall survival
(A) Progression-free survival and (B) overall survival (OS) in the treatment per protocol 
population. HR=hazard ratio.
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Figure 3. 
Kaplan-Meier estimates of progression-free survival (PFS) by MET IHC status (positive vs. 
negative) and cabozantinib exposure (any or none).
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Table 2
Efficacy endpoints
Erlotinib (n=38) Cabozantinib (n=38) Erlotinib plus Cabozantinib (n=35)
Progression-free survival
Deaths or disease progression 36 (95%) 34 (89%) 30 (86%)
Median progression-free survival, months (95% CI) 1.8 (1.7–2.2) 4.3 (3.6–7.4) 4.7 (2.4–7.4)
Overall survival
Deaths 30 (79%) 29 (76%) 19 (54%)
Median overall survival, months (95% CI) 5.1 (3.3–9.3) 9.2 (5.1–15.0) 13.3 (7.6-NR)
Best overall response
Complete response 0 0 0
Partial response 1 (3%) 4 (11%) 1 (3%)
Stable disease 6 (16%) 19 (50%) 16 (46%)
Progressive disease 25 (66%) 9 (24%) 8 (23%)
Not evaluable/not assessed 6 (16%) 6 (16%) 10 (29%)
Data are n (%) unless otherwise indicated. NR = not reached
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